Treatment of Voiding LUTS

No abstract is available for this paper.

• Publication year

  2019

• Venue

  Lower Urinary Tract Symptoms in Adults

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/978-3-030-27747-5_5
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Evaluation of the therapeutic effect against benign prostatic hyperplasia and the active constituents from Epilobium angustifolium L.

  2019cited by this paper
• Bladder decompensation and reduction in nerve density in a rat model of chronic bladder outlet obstruction are attenuated with the NLRP3 inhibitor glyburide.

  2019cited by this paper
• ASP6432, a type 1 lysophosphatidic acid receptor antagonist, reduces urethral function during urine voiding and improves voiding dysfunction

  2019cited by this paper
• Hexane fraction of Annona muricata (Sour sop) seed ameliorates testosterone-induced benign prostatic hyperplasia in rats.

  2019cited by this paper
• Effect of Veratrum maackii on Testosterone Propionate-Induced Benign Prostatic Hyperplasia in Rats.

  2019cited by this paper
• What's New in TIND?

  2018cited by this paper
• Iodine prevents the increase of testosterone‐induced oxidative stress in a model of rat prostatic hyperplasia

  2018cited by this paper
• Intraprostatic injections for lower urinary tract symptoms/benign prostatic enlargement treatment.

  2018cited by this paper
• A randomised, placebo‐controlled, multicentre, Phase 2 clinical trial to evaluate the efficacy and safety of GV1001 in patients with benign prostatic hyperplasia

  2018cited by this paper
• Terminology report from the International Continence Society (ICS) Working Group on Underactive Bladder (UAB)

  2018cited by this paper
• Effect of sorghum ethyl-acetate extract on benign prostatic hyperplasia induced by testosterone in Sprague–Dawley rats

  2018cited by this paper
• Long-term Safety and Efficacy of Mirabegron and Solifenacin in Combination Compared with Monotherapy in Patients with Overactive Bladder: A Randomised, Multicentre Phase 3 Study (SYNERGY II).

  2018cited by this paper
• Embarking Effect of ACE2-Angiotensin 1-7/Mas Receptor Axis in Benign Prostate Hyperplasia.

  2018cited by this paper
• Benign prostatic hypertrophy: Pycnogenol® supplementation improves prostate symptoms and residual bladder volume.

  2018cited by this paper
• Effects of an EP2 and EP3 Receptor Dual Agonist, ONO‐8055, on a Radical Hysterectomy‐Induced Underactive Bladder Model in Monkeys

  2018cited by this paper
• Intravesical Activation of the Cation Channel TRPV4 Improves Bladder Function in a Rat Model for Detrusor Underactivity.

  2018cited by this paper
• Efficacy and safety of Afalaza in men with symptomatic benign prostatic hyperplasia at risk of progression: a multicenter, double-blind, placebo-controlled, randomized clinical trial

  2018cited by this paper
• Role of PPAR‐α agonist fenofibrate in the treatment of induced benign prostatic hyperplasia with dysplastic changes in rats

  2018cited by this paper
• Is Sexual Function Better Preserved After Water Vapor Thermal Therapy or Medical Therapy for Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia?

  2018cited by this paper
• Banana Flower Extract Suppresses Benign Prostatic Hyperplasia by Regulating the Inflammatory Response and Inducing G1 Cell-cycle Arrest

  2018cited by this paper
• 3‐Year follow‐up of temporary implantable nitinol device implantation for the treatment of benign prostatic obstruction

  2018cited by this paper
• Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia.

  2018cited by this paper
• Combination treatment with mirabegron and solifenacin in patients with overactive bladder: exploratory responder analyses of efficacy and evaluation of patient-reported outcomes from a randomized, double-blind, factorial, dose-ranging, Phase II study (SYMPHONY)

  2017cited by this paper
• Incidence of urinary retention during treatment with single tablet combinations of solifenacin+tamsulosin OCAS™ for up to 1 year in adult men with both storage and voiding LUTS: A subanalysis of the NEPTUNE/NEPTUNE II randomized controlled studies

  2017cited by this paper
• Pharmacodynamic evaluation of Lys5, MeLeu9, Nle10-NKA(4–10) prokinetic effects on bladder and colon activity in acute spinal cord transected and spinally intact rats

  2017cited by this paper
• New therapeutic directions to treat underactive bladder

  2017cited by this paper
• Serotonin regulates prostate growth through androgen receptor modulation

  2017cited by this paper
• Comparative Effectiveness of Newer Medications for Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: A Systematic Review and Meta-analysis.

  2017cited by this paper
• Underactive bladder: Pathophysiology and clinical significance

  2017cited by this paper
• Update on minimally invasive surgery and benign prostatic hyperplasia

  2017cited by this paper
• Aquablation of the Prostate for Symptomatic Benign Prostatic Hyperplasia: Early Results

  2017cited by this paper
• Inhibition of agonist‐induced smooth muscle contraction by picotamide in the male human lower urinary tract outflow region

  2017cited by this paper
• Convective Radiofrequency Water Vapor Thermal Therapy with Rezūm System

  2017cited by this paper
• Dapoxetine attenuates testosterone-induced prostatic hyperplasia in rats by the regulation of inflammatory and apoptotic proteins.

  2016cited by this paper
• Pharmacotherapy in detrusor underactivity: A new challenge for urologists and pharmacologists (from lab to clinic)

  2016cited by this paper
• Prostatic Urethral Lift: A Unique Minimally Invasive Surgical Treatment of Male Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia.

  2016cited by this paper
• Aquablation – image‐guided robot‐assisted waterjet ablation of the prostate: initial clinical experience

  2016cited by this paper
• α1-Blockers Improve Benign Prostatic Obstruction in Men with Lower Urinary Tract Symptoms: A Systematic Review and Meta-analysis of Urodynamic Studies.

  2016cited by this paper
• Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE).

  2016cited by this paper
• Intraprostatic Botulinum Neurotoxin Type A Injection for Benign Prostatic Hyperplasia—A Spotlight in Reality

  2016cited by this paper
• Sulforaphane Ameliorates Bladder Dysfunction through Activation of the Nrf2-ARE Pathway in a Rat Model of Partial Bladder Outlet Obstruction

  2016cited by this paper
• Effect of Detrusor Overactivity on Functional Outcomes After Holmium Laser Enucleation of the Prostate in Patients With Benign Prostatic Obstruction.

  2015cited by this paper
• Individual patient data from registrational trials of silodosin in the treatment of non‐neurogenic male lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH): subgroup analyses of efficacy and safety data

  2015cited by this paper
• α1-Blockers in the management of acute urinary retention secondary to benign prostatic hyperplasia: a systematic review and meta-analysis

  2015cited by this paper
• Systematic review and meta-analysis on phosphodiesterase 5 inhibitors and α-adrenoceptor antagonists used alone or combined for treatment of LUTS due to BPH

  2015cited by this paper
• Intradetrusor injection of adult muscle-derived cells for the treatment of underactive bladder: pilot study

  2015cited by this paper
• Prostatic urethral lift: a novel approach for managing symptomatic BPH in the aging man.

  2015cited by this paper
• EAU Guidelines on the Assessment of Non-neurogenic Male Lower Urinary Tract Symptoms including Benign Prostatic Obstruction.

  2015cited by this paper
• A randomized controlled study of the efficacy of tamsulosin monotherapy and its combination with mirabegron for overactive bladder induced by benign prostatic obstruction.

  2015cited by this paper
• Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony).

  2015cited by this paper
• Treatment satisfaction and clinically meaningful symptom improvement in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: Secondary results from a 6‐month, randomized, double‐blind study comparing finasteride plus tadalafil with finasteride pl

  2015cited by this paper
• Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: results from the NEPTUNE Study and NEPTUNE II open-label extension.

  2015cited by this paper
• Temporary implantable nitinol device (TIND): a novel, minimally invasive treatment for relief of lower urinary tract symptoms (LUTS) related to benign prostatic hyperplasia (BPH): feasibility, safety and functional results at 1 year of follow‐up

  2015cited by this paper
• Excitatory effects of bombesin receptors in urinary tract of normal and diabetic rats in vivo.

  2014cited by this paper
• Medical Treatment of LUTS/BPH

  2014cited by this paper
• Multicentre prospective crossover study of the ‘prostatic urethral lift’ for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia

  2014cited by this paper
• 4-Aminopyridine Improves Lower Urinary Tract Symptoms in a Patient With Benign Prostatic Hyperplasia and Downbeat Nystagmus Syndrome

  2014cited by this paper
• Vaginal estrogen use in postmenopausal women with pelvic floor disorders: systematic review and practice guidelines

  2014cited by this paper
• Detrusor underactivity and the underactive bladder: a new clinical entity? A review of current terminology, definitions, epidemiology, aetiology, and diagnosis.

  2014cited by this paper
• Efficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia.

  2014cited by this paper
• Systematic review and meta‐analysis of the clinical effectiveness of bipolar compared with monopolar transurethral resection of the prostate (TURP)

  2014cited by this paper
• Comparative randomized study on the efficaciousness of endoscopic bipolar prostate resection versus monopolar resection technique. 3 year follow-up.

  2013cited by this paper
• Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial.

  2013cited by this paper
• Impact of vulvovaginal health on postmenopausal women: a review of surveys on symptoms of vulvovaginal atrophy

  2013cited by this paper
• EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction.

  2013cited by this paper
• Holmium Laser Enucleation of the Prostate Versus Transurethral Resection of the Prostate: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

  2013cited by this paper
• Prospective, randomized, double-blind, vehicle controlled, multicenter phase IIb clinical trial of the pore forming protein PRX302 for targeted treatment of symptomatic benign prostatic hyperplasia.

  2013cited by this paper
• Systematic review of combination drug therapy for non-neurogenic male lower urinary tract symptoms.

  2013cited by this paper
• Systematic review and meta-analysis of randomized controlled trials evaluating silodosin in the treatment of non-neurogenic male lower urinary tract symptoms suggestive of benign prostatic enlargement

  2013cited by this paper
• Finasteride monotherapy maintains stable lower urinary tract symptoms in men with benign prostatic hyperplasia following cessation of alpha blockers.

  2013cited by this paper
• A comparative study of thulium laser resection of the prostate and bipolar transurethral plasmakinetic prostatectomy for treating benign prostatic hyperplasia

  2013cited by this paper
• Midterm results from an international multicentre randomised controlled trial comparing bipolar with monopolar transurethral resection of the prostate.

  2013cited by this paper
• Serenoa repens monotherapy for benign prostatic hyperplasia (BPH): an updated Cochrane systematic review

  2012cited by this paper
• Thulium laser versus holmium laser transurethral enucleation of the prostate: 18-month follow-up data of a single center.

  2012cited by this paper
• Anti‐androgenic effects of S‐40542, a novel non‐steroidal selective androgen receptor modulator (SARM) for the treatment of benign prostatic hyperplasia

  2012cited by this paper
• Thulium Laser (Revolix) Vapoenucleation of the Prostate Is a Safe Procedure in Patients with an Increased Risk of Hemorrhage

  2012cited by this paper
• The Floppy Iris Syndrome – What Urologists and Ophthalmologists Need to Know

  2012cited by this paper
• The role of prostanoids in urinary bladder physiology

  2012cited by this paper
• A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia.

  2012cited by this paper
• Five-Year Follow-Up Results of a Randomized Controlled Trial Comparing Bipolar Plasmakinetic and Monopolar Transurethral Resection of the Prostate

  2012cited by this paper
• Comparison of 120–200 W 2 μm Thulium:Yttrium-Aluminum-Garnet Vapoenucleation of the Prostate

  2012cited by this paper
• Preservation of sexual function with the prostatic urethral lift: a novel treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia.

  2012cited by this paper
• &agr;-Blockers for benign prostatic hyperplasia: the new era

  2012cited by this paper
• A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with alpha-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia

  2012cited by this paper
• Update on AUA guideline on the management of benign prostatic hyperplasia.

  2011cited by this paper
• Solifenacin as add-on therapy for overactive bladder symptoms in men treated for lower urinary tract symptoms--ASSIST, randomized controlled study.

  2011cited by this paper
• Complications and Clinical Outcome 18 Months After Bipolar and Monopolar Transurethral Resection of the Prostate

  2011cited by this paper
• Outcomes and complications after 532 nm laser prostatectomy in anticoagulated patients with benign prostatic hyperplasia.

  2011cited by this paper
• The effects of dutasteride or tamsulosin alone and in combination on storage and voiding symptoms in men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH): 4‐year data from the Combination of Avodart and Tamsulosin (CombAT) study

  2011cited by this paper
• Bipolar plasma vaporization vs monopolar and bipolar TURP-A prospective, randomized, long-term comparison.

  2011cited by this paper
• Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe.

  2011cited by this paper
• Holmium laser enucleation of the prostate: long-term durability of clinical outcomes and complication rates during 10 years of followup.

  2011cited by this paper
• Randomized Controlled Trial to Treat Benign Prostatic Hyperplasia with Overactive Bladder Using an Alpha‐blocker Combined with Anticholinergics

  2011cited by this paper
• Thulium:YAG vapoenucleation in large volume prostates.

  2011cited by this paper
• GreenLight HPS 120-W laser vaporization versus transurethral resection of the prostate for treatment of benign prostatic hyperplasia: a randomized clinical trial with midterm follow-up.

  2010cited by this paper
• A randomized trial of photoselective vaporization of the prostate using the 80‐W potassium‐titanyl‐phosphate laser vs transurethral prostatectomy, with a 1‐year follow‐up

  2010cited by this paper
• Comparison of 2-microm continuous wave laser vaporesection of the prostate and transurethral resection of the prostate: a prospective nonrandomized trial with 1-year follow-up.

  2010cited by this paper
• Bipolar transurethral resection in saline vs traditional monopolar resection of the prostate: results of a randomized trial with a 2‐year follow‐up

  2010cited by this paper
• Recurrent urinary tract infections in women: diagnosis and management.

  2010cited by this paper
• A widespread population study of actual medical management of lower urinary tract symptoms related to benign prostatic hyperplasia across Europe and beyond official clinical guidelines.

  2010cited by this paper

• No citing papers are available for this paper.